This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following clinical trials with surrogate outcomes that did not demonstrate net benefits.

This Viewpoint discusses the death of a patient caused by unregulated biological products and efforts to encourage federal government oversight of such products.

In this issue of JAMA, Wolf et al found that during the period from 2019 to 2021, the US experienced the greatest increase in all-cause pediatric fatalities (aged 1-19 years) in more than 50 years, with increased mortality disproportionately resulting from preventable injuries. Importantly, the authors identified widening racial and ethnic disparities...

Listen to the JAMA Editor’s Audio Summary for an overview and discussion of the important articles appearing in this week’s issue of JAMA.

This cross-sectional study compares all-cause and cause-specific mortality trends and rates among youth from different races and ethnicities between 1999 and 2021.